STOCKHOLM, Sweden & RADNOR, PA, USA I December 30, 2024 I Immedica Pharma AB (Immedica), a leading global rare disease company, and Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical ...

BASEL, Switzerland I 30, 2024 I Novartis today announced positive topline results from the Phase III STEER study. This pivotal study assessed the ...

MELBOURNE, Australia and INDIANAPOLIS, IN, USA I December 30, 2024 I Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces that it has submitted its Biologics ...

New indication based on results from a global Phase 3 trial demonstrating TEVIMBRA plus chemotherapy significantly improved overall survival for patients with ...

TOKYO, Japan & MUNICH, Germany I4, 2024 I Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the ...

First and only EGFR inhibitor and targeted treatment approved in the EU in unresectable NSCLC . Approval based on LAURA Phase III trial results which showed Tagrisso extended medi ...

MD, USA I3, 2024 I Today, the U.S. Food and Drug Administration approved the first generic referencing Victoza (liraglutide ...

PARIS, France and Parsippany, NJ, USA I December 17, 2024 I Sanofi and Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd., today announced that the RELIEVE UCCD phase 2b study ...

Jemincare receives $35 million upfront payment, up to $672.5 million in milestone payments and high single-digit to low-double digit royalties on future sales – – Jemincare is currently conducting ...

NEW YORK, NY, USA I, 2024 I Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® ...

TOKYO, Japan I December 25, 2024 I Axcelead Drug Discovery Partners, Inc. (HQ: Fujisawa, Kanagawa, Japan; “Axcelead DDP”) announced today that it has entered into a drug discovery service agreement ...